OTS.at - aktuelle Inhalte in Text, Bild, Ton und Video

Acousia Therapeutics GmbH

Acousia Therapeutics Reaches 50% Patient Enrollment Milestone in Phase 2 PROHEAR Study

Tübingen, Germany (OTE) - Acousia Therapeutics GmbH announced that it has successfully enrolled 50% of patients in its ongoing Phase 2 clinical trial, the PROHEAR Study , evaluating ACOU085 (INN: bimokalner) for...

29.04.2025, 09:02:47
/
OTE0001

Acousia Therapeutics GmbH

Acousia Therapeutics to present its clinical Phase 2 PROHEAR study on hearing loss treatment candidate ACOU085 at upcoming confere

Tübingen, Germany (OTE) - Acousia Therapeutics GmbH, a Tübingen-based clinical stage biotech company focused on the enhancement and preservation of natural hearing, will be presenting the ACOU085 Phase 2 PROHEAR...

12.08.2024, 09:01:18
/
OTE0001

Acousia Therapeutics GmbH

Hearing loss company Acousia announces first patient enrolled in its Phase 2 PROHEAR-Study

Tübingen, Germany (ots) - Acousia Therapeutics GmbH, a Tübingen-based clinical stage biotech company focused on the enhancement and preservation of natural hearing, just announced the randomization of the first...

15.02.2024, 09:01:42
/
OTE0001

Acousia Therapeutics GmbH

Acousia Therapeutics attracts new investor on its path to make hearing loss a treatable disease

Tübingen (ots) - Acousia Therapeutics GmbH, a clinical-stage biotech company developing drug candidates against acute and chronic forms of hearing loss, proudly announces Esperante Ventures as the latest addition...

09.01.2024, 10:00:50
/
OTE0001

Acousia Therapeutics GmbH

Hearing Loss Company Acousia Therapeutics Green Lighted for Game-Changing Phase 2 Trial

Tübingen, Germany (ots) - Acousia Therapeutics, a pioneer clinical-stage biotech company focused on the development of novel drug therapies for the prevention and treatment of acute and chronic forms of hearing...

09.10.2023, 10:00:52
/
OTE0002

Acousia Therapeutics GmbH

Hearing loss company Acousia Therapeutics to present key learnings and data from lead development programs at US and European meetings in August and September

Tübingen, Germany (ots) - Acousia Therapeutics GmbH to share key learnings and data from its lead candidate development programs — clinical stage ACOU085 and late preclinical stage ACOU082 — during four presentations...

23.08.2023, 10:01:27
/
OTE0001

Acousia Therapeutics GmbH

Hearing loss company Acousia Therapeutics completes clinical Phase 1 study with its small molecule

Tübingen, Germany (ots) - Hearing loss company Acousia Therapeutics GmbH announced the successful completion of its ACOU085 clinical Phase 1b study today, following the final visit of the last patient treated with...

12.12.2022, 10:03:36
/
OTE0001

Acousia Therapeutics GmbH

Hearing loss company Acousia Therapeutics to present data for lead candidates ACOU085 & ACOU082 at ARO 2023 MidWinter Meeting February 11–15

Tübingen, Germany (ots) - Acousia Therapeutics GmbH, and its partners from the Translational Hearing Research Group at the Tübingen Hearing Research Center (Department of Otolaryngology, Head and Neck Surgery, University...

24.11.2022, 10:01:15
/
OTE0001

Acousia Therapeutics GmbH

Acousia Therapeutics to present its first-in-class hearing loss treatment program with ACOU085 at the 2nd Inner Ear Therapeutics Summit in Boston

Tübingen (ots) - Acousia Therapeutics GmbH will be presenting data on the company’s clinical stage, first-in-class lead candidate ACOU085 at the Hanson Wade 2nd Inner Ear Therapeutics Summit to be held in person...

11.05.2022, 10:00:51
/
OTE0001

Acousia Therapeutics GmbH

Hearing loss company Acousia Therapeutics: first patient with age-related hearing loss treated with ACOU085

Tübingen (ots) - ACOU085, the lead candidate from Acousia Therapeutics, has been administered to the first patient with age-related hearing loss (presbycusis) in a Phase 1b clinical study in Germany. The pre-screening...